Degron Fusion Constructs for Selective TDP-43 and Huntingtin Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurological diseases caused by protein misfolding and aggregation, such as ALS and Huntington's disease, face challenges like poor drug selectivity and resistance, making it difficult to effectively target and degrade disease-causing proteins and aggregates.
Innovation Solution
Development of degrons and chimeric molecules comprising a degron and a binding moiety, such as scFv antibodies, to specifically target proteins like TDP-43 and huntingtin for degradation via the ubiquitin-proteasome system or autophagy, promoting their clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to target disease-causing proteins, then some protein degradation may be achieved, but drug selectivity is poor and therapy resistance develops
Solution Approach 1:
The patent introduces a degron tag as an intermediary element that mediates between the binding moiety (antibody) and the protein degradation machinery (ubiquitin-proteasome system). This intermediary enables highly specific targeting by allowing the antibody to recognize the disease-causing protein with high affinity while the degron tag recruits the degradation system, thereby resolving the contradiction between achieving therapeutic efficacy and maintaining drug selectivity.
Solution Approach 2:
The invention creates a composite therapeutic molecule consisting of three distinct components: a binding moiety (antibody) for specific recognition, a linker for structural connection, and a degron tag for degradation signaling. This composite structure combines the advantages of high-specificity antibody binding with the potent protein-degradation capability of the ubiquitin-proteasome system, overcoming the limitations of traditional small molecule inhibitors.
2Quantity of substance
If RNA interference is used to reduce gene expression, then protein expression may be reduced, but it is inefficient for diseases with protein aggregates and challenging to target repetitive GC-rich sequences
Solution Approach 1:
Instead of trying to prevent protein aggregation through gene silencing (which fails with GC-rich repetitive sequences), the invention converts the aggregated proteins into a therapeutic target. The antibody-degron construct specifically binds to and marks the aggregated disease-causing proteins for degradation, transforming the harmful aggregates into recognizable targets that can be eliminated by the cell's own degradation machinery.
3Adaptability or versatility
If no direct protein degradation approach is used, then current therapies remain limited, but developing new approaches increases device complexity
Solution Approach 1:
The therapeutic molecule is segmented into three functional modules: a binding moiety (antibody) for target recognition, a linker for structural connection, and a degron tag for degradation signaling. This segmentation allows each component to perform its specific function optimally while maintaining overall molecular stability, making the complex construct manageable and effective.
Solution Approach 2:
The degron tag serves as a universal component that can be attached to different binding moieties targeting various disease-causing proteins. This multi-functional design allows the same degradation mechanism to be applied across different neurodegenerative diseases, reducing the need for disease-specific degradation machinery and simplifying the overall therapeutic platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric molecules effectively reduce the levels of target proteins and aggregates, offering a direct therapeutic approach to treat diseases like ALS and Huntington's disease by enhancing protein degradation.
Implementation Method 1
specifically target proteins like TDP-43 and huntingtin for degradation via the ubiquitin-proteasome system or autophagy
Implementation Method 2
specifically target proteins like TDP-43 and huntingtin for degradation via the ubiquitin-proteasome system or autophagy
Data Source
AI summary
Provided herein are degrons, compositions, and chimeric molecules comprising the degrons, and methods of using the degrons and chimeric molecules.